Feature | June 02, 2014

St. Jude Medical Completes Acquisition of CardioMEMS

June 2, 2014 — St. Jude Medical announced the completion of its acquisition of the privately held CardioMEMS Inc., developer of the CardioMEMS heart failure (HF) management system. The acquisition was completed on May 30, 2014.

“St. Jude Medical’s acquisition of CardioMEMS shows our commitment to providing innovative medical device solutions that reduce the burden of complex diseases like heart failure, both on patients and healthcare systems. The CardioMEMS HF system achieves this goal by setting a new treatment paradigm for heart failure that reduces hospitalizations and improves the quality of life for patients,” said Daniel J. Starks, chairman, president and CEO of St. Jude Medical.

The CardioMEMS HF system is the first and only U.S. Food and Drug Administration (FDA)-approved heart failure monitoring device proven to significantly reduce hospital admissions when used by physicians to manage heart failure. St. Jude Medical will now begin its strategic launch of the CardioMEMS HF system in the United States.

The CardioMEMS HF system allows clinicians to stabilize pulmonary artery pressures by proactively managing medications and other treatment options while also providing an early indication of worsening heart failure, thereby improving heart failure patients’ quality of life, and reducing economic risks for hospitals and payers.

Bank of America Merrill Lynch acted as financial advisor and Gibson, Dunn & Crutcher LLP as legal counsel to St. Jude Medical. J.P. Morgan Securities LLC acted as financial advisor to CardioMEMS and Cooley LLP as legal counsel.

For more information: www.sjm.com

Related Content

CardioKinetix, Parachute device, heart failure, 500th implantation, PARACHUTE IV Trial
News | Heart Failure| July 22, 2016
CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning...
Dictum Health, telehealth study, IDM100 tablet, neonate cardiology, in-home monitoring
Technology | Telecardiology| July 19, 2016
Dictum Health Inc. announced the launch of a post-U.S. Food and Drug Administration (FDA)-approval study of its end-to-...
SunTech Medical, SunTech CT40 sot-check vital signs device, FDA approval
Technology | Peripheral Arterial Disease (PAD)| July 18, 2016
Blood pressure technology company SunTech Medical received U.S. Food and Drug Administration (FDA) approval for...
University of Guelph study, heart failure risk, gender, aging
News | Heart Failure| July 08, 2016
University of Guelph researchers have uncovered a possible clue as to why women have lower rates of heart failure than...
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
News | Heart Failure| July 05, 2016
A research team has developed a new electric mesh device that can be wrapped around the heart to deliver electrical...
HeartWare, HVAD, batteries recall
News | Ventricular Assist Devices (VAD)| July 05, 2016
HeartWare Inc. announced a recall of the batteries used on the HeartWare Ventricular Assist Device (HVAD) because the...
beta-blockers, Thomas Jefferson University, beta-adrenergic receptors

Selective activation of the beta2-adrenergic receptor (beta2AR) by a beta-arrestin-biased pepducin promotes activation of a beta-arrestin signaling pathway that is cardioprotective. Image courtesy of the lab of Jeffrey Benovic, Thomas Jefferson University.

News | Heart Failure| June 30, 2016
Researchers at Thomas Jefferson University have discovered how to enhance the effectiveness of beta-blockers for heart...
Sponsored Content | Videos | Cardio-oncology| June 30, 2016
Interview with Federico Asch, M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health
Overlay Init